Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13389472 | 1.00 | AAK1 (0.38) | AAK1MMP13CA14CA12DGAT1 | |
| SCHEMBL27092235 | 0.86 | AAK1 (0.38) | AAK1MMP13CA14CA12DGAT1 | |
| SCHEMBL30743001 | 0.86 | AAK1 (0.38) | AAK1MMP13CA14CA12DGAT1 | |
| SCHEMBL18235375 | 0.86 | AAK1 (0.38) | AAK1MMP13CA14CA12DGAT1 | |
| SCHEMBL24297646 | 0.85 | AAK1 (0.37) | AAK1MMP13CA14CA12DGAT1 | |
| SCHEMBL1742075 | 0.85 | MMP13 (0.39) | AAK1MMP13CA14CA12DGAT1 | |
| SCHEMBL9634202 | 0.84 | CA14 (0.36) | CA14CA12DGAT1HDAC6HDAC1 | |
| SCHEMBL9634197 | 0.84 | CA14 (0.36) | CA14CA12DGAT1HDAC6HDAC1 | |
| SCHEMBL21646813 | 0.84 | AAK1 (0.37) | AAK1MMP13CA14 | |
| SCHEMBL24093716 | 0.83 | AAK1 (0.49) | AAK1MMP13CA14CA12DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828993-B2 | Psychotropic agents having glutamate NMDA activity | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-09-09 | — | — | US | disclosed |
| US-20130131048-A1 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-05-23 | — | — | US | disclosed |
| US-8394790-B2 | Psychotropic agents having glutamate NMDA activity | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-03-12 | — | — | US | disclosed |
| US-20100093704-A1 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD (IL) | 2010-04-15 | — | — | US | disclosed |
| EP-2077860-A2 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | Ramot at Tel-Aviv University Ltd (IL) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008050341-A2 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD (IL) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131048-A1 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | GRIN1, GRIN2A, GRIN2B | AAK1 696/4885MMP13 4627/4885CA14 3166/4885 |
| US-20100093704-A1 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | GRIN1, GRIN2A, GRIN2B | AAK1 696/4885MMP13 4627/4885CA14 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.